Skip to main contentScroll Top

Beyond Section 3(D): Comparing India’s and America’s Legal Answers to Pharmaceutical Evergreening

Beyond Section 3(D): Comparing India’s and America’s Legal Answers to Pharmaceutical Evergreening

Author's Details -

Amritha Sudheesh (Manipal Law School, Yelahanka, Bengaluru, India)

Received 10 September 2026; Accepted 10 October 2026; Published 14 October 2026

Cite this Paper: Amritha Sudheesh, 'Beyond Section 3(D): Comparing India’s and America’s Legal Answers to Pharmaceutical Evergreening' (2026) 7(1) Jus Corpus Law Journal 488-495 <https://doi.org/10.66918/juscorpus.v7i1.2026.35>

Category: Short Article

Pagination: 488-495

A patent provides a creator with a temporary monopoly in exchange for ensuring that the public is informed of how the invention functions. Once this period has elapsed, generic items may enter the market, and costs decrease. However, pharmaceutical companies have figured out how to prolong this situation. They register patents for minor alterations of a current drug, such as a new coating, a new salt, or a new dosage, at a time when the original patent is about to expire. The analysis in this article focuses on how India and the United States manage the situation. India relies heavily on its patent law, section 3(d), which bars the issuance of patents on new versions of existing drugs unless they are effective. The Supreme Court applied this law in the famous Novartis case in 2013, and the patent office has again used it to deny patents on Bedaquiline (2023) and Dolutegravir (2024). But section 3(d) is not the only method in India in this situation. Unlike India, the USA does not have any law that resembles India; in Novartis v Union of India, the Supreme Court prevented the patent under section 3(d). However, it stops evergreening afterwards through antitrust principles and ‘pay-for-delay’ settlements, for instance, FTC v Actavis (2013). Both countries follow different approaches but share the same aim of ensuring companies receive monopolistic rights only if they have invented something novel.
Paper Type Journal Info Creative Commons Copyright

Short Article

Jus Corpus Law Journal

Vol 7 Issue 1

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© Jus Corpus Law Journal 2026

All rights reserved.